… to progress to castration-resistance is the key to developing future therapy. … castration
resistance, the agents currently available for treatment of CRPC, and the mechanisms of resistance …

… of (or with) prostate cancer. Resistance to chemotherapy in metastatic CRPC is a result of
cellular mechanisms of drug resistance intrinsic to prostate cancer and general mechanisms …

… sensitive prostate cancer to castration-resistant prostate cancer (… While up to 30% of patients
have primary resistance to these … , all patients inevitably develop resistance to treatment and …

… clinical benefit in the setting of castration resistance. The original approval in Europe of …
for locally advanced prostate cancer was based on the results of the Early Prostate Cancer trial, …

… Patients with castration-resistant prostate cancer (CRPC), who … the mechanisms of prostate
cancer resistance, possible … -refractory metastatic castration resistant prostatic cancer. In the …

… of eradicating the spread of prostate cancer is now being closely examined. This review
provides different aspects of development of castration resistance. The elucidation of these …

… important mechanisms responsible for castration resistance in prostate cancer (Figure 2b). …
and its protein is causally associated with castration resistance. Elevated levels of AR also …

Patients with metastatic castration-resistant prostate cancer (mCPRC) now have an
unprecedented number of approved treatment options, including chemotherapies (docetaxel, …

… (CRPC) is an advanced form of prostate cancer characterised by disease progression …
deprivation) castration. The process by which prostate cancer cells become castrate resistant is …

… Another mechanism of castration resistance is prostate cancer is gain of function mutations
in the AR. As with splicing variants, clinically relevant point mutations predominantly affect …